** Shares of drug developer Tectonic Therapeutic TECX.O rise ~104% to $52.50, set for record single-day pct gain
** TECX says its experimental drug, TX45, showed improved blood flow and reduced pressure in lungs and heart in an early-stage trial
** TECX is testing TX45 to treat patients with group 2 pulmonary hypertension, a condition where high lung blood pressure is caused by left-sided heart disease, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and feet
** TX45 was well-tolerated and had no serious side effects in patients - TECX
** The condition currently has no approved treatments
** TECX more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.